Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kewaunee Scientific (KEQU) Asset Writedowns and Impairment (2016 - 2026)

Kewaunee Scientific (KEQU) has 16 years of Asset Writedowns and Impairment data on record, last reported at -$50000.0 in Q4 2025.

  • For Q4 2025, Asset Writedowns and Impairment fell 516.67% year-over-year to -$50000.0; the TTM value through Oct 2025 reached $14000.0, down 87.72%, while the annual FY2025 figure was $68000.0, 75.36% down from the prior year.
  • Asset Writedowns and Impairment reached -$50000.0 in Q4 2025 per KEQU's latest filing, down from $19000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $125000.0 in Q3 2023 and bottomed at -$52000.0 in Q2 2025.
  • Average Asset Writedowns and Impairment over 5 years is $24250.0, with a median of $21000.0 recorded in 2022.
  • The widest YoY moves for Asset Writedowns and Impairment: up 1028.57% in 2022, down 520.0% in 2022.
  • A 5-year view of Asset Writedowns and Impairment shows it stood at -$5000.0 in 2021, then crashed by 520.0% to -$31000.0 in 2022, then surged by 293.55% to $60000.0 in 2023, then tumbled by 80.0% to $12000.0 in 2024, then crashed by 516.67% to -$50000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Asset Writedowns and Impairment were -$50000.0 in Q4 2025, $19000.0 in Q3 2025, and -$52000.0 in Q2 2025.